Human Microbiome Market Poised for Exponential Growth - Projected to Surpass USD 3.35 Billion by 2031 at 30.5% CAGR

QY Research has recently published a report, titled "Human Microbiome Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". The global Human Microbiome market is comprehensively analyzed in the report with the main objective of providing accurate market data and useful recommendations to help players to gain strong growth in future. The report is compiled by subject matter experts and experienced market analysts, which makes it highly authentic and reliable. Readers are provided with deep analysis of historical and future market scenarios to get sound understanding of market competition and other important aspects. The report offers exhaustive research on market dynamics, key segments, leading players, and different regional markets. It is a complete package of thorough analysis and research on the global Human Microbiome market.

The global market for Human Microbiome was estimated to be worth US$ 568 million in 2024 and is forecast to a readjusted size of US$ 3351 million by 2031 with a CAGR of 30.5% during the forecast period 2025-2031.

Get PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.in/request-sample/medical-care-human-microbiome-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

The Human Microbiome refers to the collective microorganisms and their genetic material residing in various parts of the human body, such as the gut, skin, mouth, respiratory tract, and reproductive system. These microbes form a symbiotic relationship with the human host, playing critical roles in immune modulation, nutrient absorption, metabolic regulation, and disease prevention. With the advancement of high-throughput sequencing, synthetic biology, and artificial intelligence, the commercialization of the microbiome is shifting from basic research toward precision medicine, immunotherapy, probiotics, functional foods, and personalized nutrition. The global human microbiome industry is now entering an accelerated application phase, becoming a model for cross-border integration across healthcare, biotechnology, and nutrition sectors, and attracting major pharmaceutical and biotech companies, as well as emerging startups.

The human microbiome sector has gained momentum due to rising demand for precision medicine, chronic disease management, and alternatives to antibiotics. Increasing evidence from Phase III clinical trials supports the role of gut microbiota in conditions such as cancer, neurological disorders, and autoimmune diseases, accelerating product development in therapeutics, diagnostics, and nutritional interventions. The U.S. and EU have included microbiome initiatives in their national-level precision medicine strategies, and investor interest continues to surge. The global market for microbiome therapeutics is projected to surpass $10 billion by 2030.

Despite the promising outlook, the industry faces significant hurdles. These include individual microbiome variability leading to inconsistent treatment efficacy, lack of standardized clinical validation pathways, and regulatory uncertainty. Technological challenges around scalable manufacturing, storage, activity control, and genomic safety further complicate commercialization. Additionally, public acceptance, ethical concerns, and low physician familiarity with microbiome-based therapies present barriers to market expansion.

Downstream, pharmaceutical, nutritional, and diagnostic companies are accelerating commercialization of microbiome-related products. There is growing demand for gut microbiome therapeutics, fecal microbiota transplantation (FMT), probiotics, and next-generation probiotics (NGPs), particularly in cancer support therapy, autism management, and inflammatory bowel disease. Rising consumer awareness of microbiome balance is also fueling demand in functional food and personalized nutrition, turning the sector into a hotbed for venture capital and strategic investment.

The competitive landscape of the global Human Microbiome market is broadly studied in the report with large focus on recent developments, future plans of top players, and key growth strategies adopted by them. The analysts authoring the report have profiled almost every major player of the global Human Microbiome market and thrown light on their crucial business aspects such as production, areas of operation, and product portfolio. All companies analyzed in the report are studied on the basis of vital factors such as market share, market growth, company size, production volume, revenue, and earnings.

Key Players Mentioned in the Global Human Microbiome Market Research Report:

Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC

The report offers great insights into important segments of the global Human Microbiome market while concentrating on their CAGR, market size, market share, and future growth potential. The global Human Microbiome market is mainly segmented according to type of product, application, and region. Each segment in these categories is extensively researched to become familiar with their growth prospects and key trends. Segmental analysis is highly important to identify key growth pockets of a global market. The report provides specific information on the market growth and demand of different products and applications to help players to focus on profitable areas of the global Human Microbiome market.

Details of Human Microbiome Market Segmentation: -

Segment by Type:

Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Others

Segment by Application:

Treatment
Diagnosis

Research Methodology

This report has been compiled using latest primary and secondary research methodologies such as data triangulation, qualitative and quantitative analysis, and top-down and bottom-up approaches. The researchers also referred to reliable secondary sources for collecting important data and statistics. All the findings of the research study have been verified and revalidated with the help of authentic primary sources.

The researchers create a unique model and customize it for each research study. Their market forecasts are based on the industry-best combination of domain expertise, industry knowledge and experience, technological analysis, and economic tools. Technological market models are generally adopted for long-term market forecasting, whereas econometric models are adopted for short-term forecasting. The researchers were provided with advanced analysis tools at the time of the preparation of the report.

Report Objectives

(1) To carefully analyze and estimate the size of the global Human Microbiome market

(2) To clearly segment the global Human Microbiome market and estimate the market size of the segments

(3) To provide details about key strategies adopted by leading players of the global Human Microbiome market

(4) To help readers understand current and future market scenarios

(5) To provide information about latest trends of the global Human Microbiome market and its key segments

(6) To assess the contribution of each region or country to the global Human Microbiome market

(7) To provide information on important drivers, restraints, and opportunities of the global Human Microbiome market

(8) To accurately calculate the market shares of key segments, regions, and companies in the global Human Microbiome market

Request Pre-Order Enquiry or Customized Research on This Report: https://www.qyresearch.in/pre-order-inquiry/medical-care-human-microbiome-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Table of Content

1 Market Overview
1.1 Human Microbiome Product Introduction
1.2 Global Human Microbiome Market Size Forecast (2020-2031)
1.3 Human Microbiome Market Trends & Drivers
1.3.1 Human Microbiome Industry Trends
1.3.2 Human Microbiome Market Drivers & Opportunity
1.3.3 Human Microbiome Market Challenges
1.3.4 Human Microbiome Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Human Microbiome Players Revenue Ranking (2024)
2.2 Global Human Microbiome Revenue by Company (2020-2025)
2.3 Key Companies Human Microbiome Manufacturing Base Distribution and Headquarters
2.4 Key Companies Human Microbiome Product Offered
2.5 Key Companies Time to Begin Mass Production of Human Microbiome
2.6 Human Microbiome Market Competitive Analysis
2.6.1 Human Microbiome Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Human Microbiome Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Microbiome as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Gastrointestinal Tract Human Micobiome
3.1.2 Urogenital Tract Human Micobiome
3.1.3 Others
3.2 Global Human Microbiome Sales Value by Type
3.2.1 Global Human Microbiome Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Human Microbiome Sales Value, by Type (2020-2031)
3.2.3 Global Human Microbiome Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Treatment
4.1.2 Diagnosis
4.2 Global Human Microbiome Sales Value by Application
4.2.1 Global Human Microbiome Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Human Microbiome Sales Value, by Application (2020-2031)
4.2.3 Global Human Microbiome Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Human Microbiome Sales Value by Region
5.1.1 Global Human Microbiome Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Human Microbiome Sales Value by Region (2020-2025)
5.1.3 Global Human Microbiome Sales Value by Region (2026-2031)
5.1.4 Global Human Microbiome Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Human Microbiome Sales Value, 2020-2031
5.2.2 North America Human Microbiome Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Human Microbiome Sales Value, 2020-2031
5.3.2 Europe Human Microbiome Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Human Microbiome Sales Value, 2020-2031
5.4.2 Asia Pacific Human Microbiome Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Human Microbiome Sales Value, 2020-2031
5.5.2 South America Human Microbiome Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Human Microbiome Sales Value, 2020-2031
5.6.2 Middle East & Africa Human Microbiome Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Human Microbiome Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Human Microbiome Sales Value, 2020-2031
6.3 United States
6.3.1 United States Human Microbiome Sales Value, 2020-2031
6.3.2 United States Human Microbiome Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Human Microbiome Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Human Microbiome Sales Value, 2020-2031
6.4.2 Europe Human Microbiome Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Human Microbiome Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Human Microbiome Sales Value, 2020-2031
6.5.2 China Human Microbiome Sales Value by Type (%), 2024 VS 2031
6.5.3 China Human Microbiome Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Human Microbiome Sales Value, 2020-2031
6.6.2 Japan Human Microbiome Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Human Microbiome Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Human Microbiome Sales Value, 2020-2031
6.7.2 South Korea Human Microbiome Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Human Microbiome Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Human Microbiome Sales Value, 2020-2031
6.8.2 Southeast Asia Human Microbiome Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Human Microbiome Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Human Microbiome Sales Value, 2020-2031
6.9.2 India Human Microbiome Sales Value by Type (%), 2024 VS 2031
6.9.3 India Human Microbiome Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Vedanta
7.1.1 Vedanta Profile
7.1.2 Vedanta Main Business
7.1.3 Vedanta Human Microbiome Products, Services and Solutions
7.1.4 Vedanta Human Microbiome Revenue (US$ Million) & (2020-2025)
7.1.5 Vedanta Recent Developments
7.2 Seres Therapeutics
7.2.1 Seres Therapeutics Profile
7.2.2 Seres Therapeutics Main Business
7.2.3 Seres Therapeutics Human Microbiome Products, Services and Solutions
7.2.4 Seres Therapeutics Human Microbiome Revenue (US$ Million) & (2020-2025)
7.2.5 Seres Therapeutics Recent Developments
7.3 Second Genome
7.3.1 Second Genome Profile
7.3.2 Second Genome Main Business
7.3.3 Second Genome Human Microbiome Products, Services and Solutions
7.3.4 Second Genome Human Microbiome Revenue (US$ Million) & (2020-2025)
7.3.5 Second Genome Recent Developments
7.4 Rebiotix
7.4.1 Rebiotix Profile
7.4.2 Rebiotix Main Business
7.4.3 Rebiotix Human Microbiome Products, Services and Solutions
7.4.4 Rebiotix Human Microbiome Revenue (US$ Million) & (2020-2025)
7.4.5 Rebiotix Recent Developments
7.5 ActoGeniX
7.5.1 ActoGeniX Profile
7.5.2 ActoGeniX Main Business
7.5.3 ActoGeniX Human Microbiome Products, Services and Solutions
7.5.4 ActoGeniX Human Microbiome Revenue (US$ Million) & (2020-2025)
7.5.5 ActoGeniX Recent Developments
7.6 Enterome BioScience
7.6.1 Enterome BioScience Profile
7.6.2 Enterome BioScience Main Business
7.6.3 Enterome BioScience Human Microbiome Products, Services and Solutions
7.6.4 Enterome BioScience Human Microbiome Revenue (US$ Million) & (2020-2025)
7.6.5 Enterome BioScience Recent Developments
7.7 AvidBiotics
7.7.1 AvidBiotics Profile
7.7.2 AvidBiotics Main Business
7.7.3 AvidBiotics Human Microbiome Products, Services and Solutions
7.7.4 AvidBiotics Human Microbiome Revenue (US$ Million) & (2020-2025)
7.7.5 AvidBiotics Recent Developments
7.8 4D Pharma Research Ltd
7.8.1 4D Pharma Research Ltd Profile
7.8.2 4D Pharma Research Ltd Main Business
7.8.3 4D Pharma Research Ltd Human Microbiome Products, Services and Solutions
7.8.4 4D Pharma Research Ltd Human Microbiome Revenue (US$ Million) & (2020-2025)
7.8.5 4D Pharma Research Ltd Recent Developments
7.9 Enterologics
7.9.1 Enterologics Profile
7.9.2 Enterologics Main Business
7.9.3 Enterologics Human Microbiome Products, Services and Solutions
7.9.4 Enterologics Human Microbiome Revenue (US$ Million) & (2020-2025)
7.9.5 Enterologics Recent Developments
7.10 Metabogen
7.10.1 Metabogen Profile
7.10.2 Metabogen Main Business
7.10.3 Metabogen Human Microbiome Products, Services and Solutions
7.10.4 Metabogen Human Microbiome Revenue (US$ Million) & (2020-2025)
7.10.5 Metabogen Recent Developments
7.11 Metabiomics
7.11.1 Metabiomics Profile
7.11.2 Metabiomics Main Business
7.11.3 Metabiomics Human Microbiome Products, Services and Solutions
7.11.4 Metabiomics Human Microbiome Revenue (US$ Million) & (2020-2025)
7.11.5 Metabiomics Recent Developments
7.12 Ritter Pharmaceuticals
7.12.1 Ritter Pharmaceuticals Profile
7.12.2 Ritter Pharmaceuticals Main Business
7.12.3 Ritter Pharmaceuticals Human Microbiome Products, Services and Solutions
7.12.4 Ritter Pharmaceuticals Human Microbiome Revenue (US$ Million) & (2020-2025)
7.12.5 Ritter Pharmaceuticals Recent Developments
7.13 Osel
7.13.1 Osel Profile
7.13.2 Osel Main Business
7.13.3 Osel Human Microbiome Products, Services and Solutions
7.13.4 Osel Human Microbiome Revenue (US$ Million) & (2020-2025)
7.13.5 Osel Recent Developments
7.14 Symberix
7.14.1 Symberix Profile
7.14.2 Symberix Main Business
7.14.3 Symberix Human Microbiome Products, Services and Solutions
7.14.4 Symberix Human Microbiome Revenue (US$ Million) & (2020-2025)
7.14.5 Symberix Recent Developments
7.15 Miomics
7.15.1 Miomics Profile
7.15.2 Miomics Main Business
7.15.3 Miomics Human Microbiome Products, Services and Solutions
7.15.4 Miomics Human Microbiome Revenue (US$ Million) & (2020-2025)
7.15.5 Miomics Recent Developments
7.16 Symbiotix Biotherapies
7.16.1 Symbiotix Biotherapies Profile
7.16.2 Symbiotix Biotherapies Main Business
7.16.3 Symbiotix Biotherapies Human Microbiome Products, Services and Solutions
7.16.4 Symbiotix Biotherapies Human Microbiome Revenue (US$ Million) & (2020-2025)
7.16.5 Symbiotix Biotherapies Recent Developments
7.17 MicroBiome Therapeutics LLC
7.17.1 MicroBiome Therapeutics LLC Profile
7.17.2 MicroBiome Therapeutics LLC Main Business
7.17.3 MicroBiome Therapeutics LLC Human Microbiome Products, Services and Solutions
7.17.4 MicroBiome Therapeutics LLC Human Microbiome Revenue (US$ Million) & (2020-2025)
7.17.5 MicroBiome Therapeutics LLC Recent Developments
8 Industry Chain Analysis
8.1 Human Microbiome Industrial Chain
8.2 Human Microbiome Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Human Microbiome Sales Model
8.5.2 Sales Channel
8.5.3 Human Microbiome Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

Contact US

Ankit Jain - Director, Global Digital Marketing

QY Research, INC.
India Office -
315Work Avenue, Raheja Woods, Kalyani Nagar,
Pune, Maharashtra 411006, India
Web - https://www.qyresearch.in
Email- ankit@qyresearch.com

About US:

QYResearch is a leading global market research and consulting company established in 2007. With over 17 years' experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability.

This release was published on openPR.